Diagnostic utility of the HepPar1 antibody to differentiate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration samples Academic Article uri icon


MeSH Major

  • Biomarkers, Tumor
  • Carcinoma, Hepatocellular
  • Cholangiocarcinoma
  • Liver Neoplasms


  • The results of the current study demonstrate that HepPar1 is an effective marker with which to differentiate between HCC and CC and/or MC. HepPar1 was found to demonstrate 100% positivity in HCC cases, compared with 0% and 15% positivity, respectively, in CC and MC cases. In addition, HepPar1 is extremely helpful in limited tissue samples from FNA. Although 15% of the MC cases in the current study were found to be positive, with the help of clinical correlation and other immunohistochemical stains a definite diagnosis could be rendered. Potential pitfalls include residual benign hepatocyte staining within a non-HCC malignancy, as was observed in one of the CC cases in the current study.

publication date

  • February 25, 2002



  • Academic Article



  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.10311

PubMed ID

  • 11836703

Additional Document Info

start page

  • 49

end page

  • 52


  • 96


  • 1